Targeted therapies mainly target gene mutations or certain signaling pathways of tumors and anti-tumor angiogenesis, specifically in lung cancer, for example. Targeted drugs can target EGFR gene mutation and ALK gene mutation, such as gefitinib, erlotinib or oxitinib for the former, and crizotinib, alectinib or ceritinib for the latter. There are also targeted drugs against tumor angiogenesis, such as bevacizumab, recombinant human vascular endothelial inhibitor, anlotinib, etc., which are used in lung cancer, mainly to reduce the blood supply to the tumor and renormalize the tumor vascular supply. Targeted drugs are the so-called immune checkpoint inhibitors, which are mainly used for immune escape during tumor development, and the main drugs are pablizumab or nitrozumab and so on. In conclusion, targeted therapy is playing an increasingly important role in the treatment of malignant tumors, and the efficiency rate is over 70% if lung cancer has genetic mutations.